Classifying risk factors for dyskinesia in Parkinson's disease

被引:84
作者
Sharma, J. C. [1 ]
Bachmann, C. G. [2 ]
Linazasoro, G. [3 ]
机构
[1] Univ Nottingham, Sherwood Forest Hosp NHS Trust, Nottingham NG7 2RD, England
[2] Univ Gottingen, Dept Clin Neurophysiol, Gottingen, Germany
[3] Fdn Inbiomed, Policlin Gipuzkoa, Ctr Invest Parkinson, San Sebastian, Spain
关键词
Dyskinesia; Levodopa dose per kilogram body weight; Risk factors; Parkinson's disease; LEVODOPA-INDUCED DYSKINESIAS; RECEPTOR GENE POLYMORPHISM; MOTOR FLUCTUATIONS; L-DOPA; BODY-WEIGHT; ONSET AGE; MOLECULAR-MECHANISMS; CLINICAL-FEATURES; ASSOCIATION; THERAPY;
D O I
10.1016/j.parkreldis.2010.06.003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Currently there is no classification of risk factors applicable to an individual patient with Parkinson's disease for the development of dyskinesia. Methods: We conducted literature search to identify and classifying risk factors into groups (a) intrinsic vs extrinsic and (b) modifiable vs non-modifiable. Results: Younger age, young age of onset and severity of PD are major intrinsic non-modifiable risk factors for dyskinesia, female gender is another factor but not independent of other factors. Genetic expression and plasticity may determine pre-disposition to age of onset of PD and dyskinesia, these are currently non-modifiable factors arising due to an interaction of intrinsic and extrinsic factors. Lower initial body weight and weight loss during the course of the disease increase the risk of dyskinesia. Levodopa dose per kilogram body weight is a more significant risk factor than absolute levodopa dose. Early use of longer acting non-levodopa (i.e. dopamine agonists) medications delays the onset of dyskinesia. Interaction between body weight, levodopa dose and mode and duration of drug delivery is a significant modifiable factor. Conclusion: Dyskinesia in PD arises as a consequence of the interaction of intrinsic versus extrinsic and modifiable versus non-modifiable factors. Identification and manipulation of modifiable factors for an individual patient may reduce the risk and burden of dyskinesia. Adjustment of levodopa dose according to body weight during the course of the disease seems to be a significant modifiable risk factor for dyskinesia. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:490 / 497
页数:8
相关论文
共 86 条
  • [1] Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature
    Ahlskog, JE
    Muenter, MD
    [J]. MOVEMENT DISORDERS, 2001, 16 (03) : 448 - 458
  • [2] Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome
    Antonini, Angelo
    Isaias, Ioannis U.
    Canesi, Margherita
    Zibetti, Maurizio
    Mancini, Francesca
    Manfredi, Luigi
    Dal Fante, Marco
    Lopiano, Leonardo
    Pezzoli, Gianni
    [J]. MOVEMENT DISORDERS, 2007, 22 (08) : 1145 - 1149
  • [3] Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease
    Arabia, G
    Zappia, M
    Bosco, D
    Crescibene, L
    Bagalà, A
    Bastone, L
    Caracciolo, M
    Scornaienghi, M
    Quattrone, A
    [J]. NEUROLOGICAL SCIENCES, 2002, 23 (Suppl 2) : S53 - S54
  • [4] Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia
    Aubert, I
    Guigoni, C
    Håkansson, K
    Li, Q
    Dovero, S
    Barthe, N
    Bioulac, BH
    Gross, CE
    Fisone, G
    Bloch, B
    Bezard, E
    [J]. ANNALS OF NEUROLOGY, 2005, 57 (01) : 17 - 26
  • [5] Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias
    Bachmann, C. G.
    Zapf, A.
    Brunner, E.
    Trenkwalder, C.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (08) : 895 - 901
  • [6] Body weight in patients with Parkinson's disease
    Bachmann, Cornelius G.
    Trenkwalder, Claudia
    [J]. MOVEMENT DISORDERS, 2006, 21 (11) : 1824 - 1830
  • [7] Is underweightness still a major problem in Parkinson's disease patients?
    Barichella, M
    Marczewska, A
    Vairo, A
    Canesi, M
    Pezzoli, G
    [J]. EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2003, 57 (04) : 543 - 547
  • [8] CHRONIC TREATMENT WITH L-DOPA, BUT NOT BROMOCRIPTINE INDUCES DYSKINESIA IN MPTP-PARKINSONIAN MONKEYS - CORRELATION WITH [H-3] SPIPERONE BINDING
    BEDARD, PJ
    DIPAOLO, T
    FALARDEAU, P
    BOUCHER, R
    [J]. BRAIN RESEARCH, 1986, 379 (02) : 294 - 299
  • [9] DOES AGING AGGRAVATE PARKINSONIAN DISABILITY
    BLIN, J
    DUBOIS, B
    BONNET, AM
    VIDAILHET, M
    BRANDABUR, M
    AGID, Y
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1991, 54 (09) : 780 - 782
  • [10] The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease - Final results of a 5-year, double-blind, Levodopa-controlled study
    Bracco, F
    Battaglia, A
    Chouza, C
    Dupont, E
    Gershanik, O
    Masso, JFM
    Montastruc, JL
    [J]. CNS DRUGS, 2004, 18 (11) : 733 - 746